Federal Register / Vol. 72, No. 37 / Monday, February 26, 2007 / Notices 8391 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Gertrude K. McFarland, 

FAAN, RN, DNSC, Scientific Review 

Administrator, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 3156, MSC 7770, Bethesda, MD 

20892, (301) 435–1784, mcfarlag@csr.nih.gov. 

Name of Committee: AIDS and Related 

Research Integrated Review Group; AIDSassociated Opportunistic Infections and 

Cancer Study Section. 

Date: March 19, 2007. 

Time: 8 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Watergate Hotel, 2650 Virginia 

Avenue, NW., Washington, DC 20037. 

Contact Person: Eduardo A. Montalvo, 

PhD, Scientific Review Administrator, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5212, 

MSC 7852, Bethesda, MD 20892, (301) 435–

1168, montalve@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Infectious 

Diseases and Microbiology Fellowships. 

Date: March 19–20, 2007. 

Time: 8:30 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: St. Gregory Hotel, 2033 M Street, 

NW., Washington, DC 20036. 

Contact Person: John C. Pugh, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3114, 

MSC 7808, Bethesda, MD 20892, (301) 435–

2398, pughjohn@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Regulation 

of Axonal Growth and Synaptic Plasticity. 

Date: March 19, 2007. 

Time: 11 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Lawrence Baizer, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4152, 

MSC 7850, Bethesda, MD 20892, (301) 435–

1257, baizerl@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Neurogenesis and Stem Cells. 

Date: March 19, 2007. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Joanne T. Fugii, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4184, 

MSC 7850, Bethesda, MD 20892, (301) 435–

1178, fujiij@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–06–

389: Basic and Translational Research 

Opportunities in the Social Neuroscience of 

Mental Health. 

Date: March 20–21, 2007. 

Time: 6 a.m. to 7 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Jane A. DoussardRoosevelt, PhD, Scientific Review 

Administrator, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 3184, MSC 7848, Bethesda, MD 

20892, (301) 435–4445, 

doussarj@csr.nih.gobv. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–06–

473 Translational Research on the 

Relationship of Anxiety and Depression 

(R21). 

Date: March 20–21, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Maribeth Champouxs, 

PhD, Scientific Review Administrator, Center 

for Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3146, 

MSC 7759, Bethesda, MD 20892, 301–594–

3163, champoum@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Neural System. 

Date: March 20, 2007. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Bernard F. Driscoll, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5184, 

MSC 7844, Bethesda, MD 20892, (301) 435–

1242, driscolb@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Heart 

Failure. 

Date: March 20, 2007. 

Time: 2:30 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Maqsood A. Wani, PhD, 

DVM, Scientific Review Administrator, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 2114, MSC 7814, Bethesda, MD 20892, 

301–435–2270, wanimaqs@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Social Sciences. 

Date: March 21, 2007. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Ann Hardy, DRPH, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3158, 

MSC 7770, Bethesda, MD 20892, (301) 435–

0695, hardyan@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Cognition. 

Date: March 21, 2007. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Bernard F. Driscoll, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5184, 

MSC 7844, Bethesda, MD 20892, (301) 435–

1242, driscolb@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; BGES 

Special Emphasis Panel Study Section–HOP 

E 02 M. 

Date: March 21, 2007. 

Time: 4 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Karin F. Helmers, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3166, 

MSC 7770, Bethesda, MD 20892, (301) 435–

1017, helmersk@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 15, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–835 Filed 2–23–07; 8:45am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Use of Recombinant Yeast 

Expressing CEA for the Prevention and 

Treatment of Cancer 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

Part 404.7(a)(1)(i), that the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive 


ycherry on PROD1PC64 with NOTICES
8392 Federal Register / Vol. 72, No. 37 / Monday, February 26, 2007 / Notices 

patent license to practice the inventions 

embodied in U.S. Patent 6,756,038 and 

PCT Application Serial No. PCT/US98/ 

19794 and foreign equivalents thereof, 

entitled ‘‘Agonist and Antagonist 

Peptides of Carcinoembryonic Antigen 

(CEA)’’ (E–099–1996/0) and U.S. Patent 

6,969,582 and PCT Application Serial 

No. PCT/US99/26866 and foreign 

equivalents thereof, entitled ‘‘A 

Recombinant Vector Expressing 

Multiple Costimulatory Molecules and 

Uses Thereof’’ (E–256–1998/0), to 

GlobeImmune Inc., which is located in 

Louisville, Colorado. The patent rights 

in these inventions have been assigned 

to the United States of America. The 

prospective exclusive license territory 

may be worldwide and the field of use 

may be limited to the use recombinant 

Saccharomyces cerevisiae expressing 

CEA for the prevention and treatment of 

cancer. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before April 

27, 2007 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: Michelle A. Booden, 

PhD., Technology Licensing Specialist, 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Telephone: (301) 451–

7337; Facsimile: (301) 402–0220; E-mail: 

boodenm@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

technology describes the composition 

and use of nucleic acid sequences that 

encode agonist and one antagonist 

peptide variants of the human 

carcinoembryonic antigen (CEA) 

peptide, including but not limited to 

CAP–1. CEA is an antigen, which is 

expressed on the surface of various 

types of cancer cells. It is capable of 

stimulating a specific cytolytic T cell 

response, as is CAP–1, which is a highly 

immunogenic epitope of CEA. 

Therefore, CAP–1 agonists which are 

capable of eliciting a CEA-specific 

cytolytic T cell response, such as those 

identified by the inventors, may 

represent potential immunogens for use 

as therapeutic agents or vaccines against 

various cancers, and possibly also for 

use against autoimmune diseases. In 

fact, at least one of the agonist peptides 

appears to be more immunogenic than 

the native CAP–1 peptide. CAP–1 

antagonists which are capable of 

reducing or eliminating this T cell 

response, such as the antagonist peptide 

variant identified by the inventors, may 

represent potential agents for use 

against autoimmune responses to CEA 

or to agonist peptide variants thereof. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR Part 404.7. The 

prospective exclusive license may be 

granted unless within sixty (60) days 

from the date of this published notice, 

the NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR Part 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: February 16, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–3153 Filed 2–23–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences 2008–2012 Strategic Plan 

ACTION: Notice with request for 

comments. 

SUMMARY: NIGMS is initiating a strategic 

planning process that will culminate in 

the NIGMS Strategic Plan for 2008–

2012. To assist with this process, 

NIGMS requests input from scientists, 

scientific organizations, and other 

interested parties. The goal of this 

strategic planning process is to identify 

Institute priorities and guide decisionmaking over the next five years. 

Information about NIGMS can be found 

at http://www.nigms.nih.gov/. 

DATES: In order to ensure full 

consideration, responses must be 

submitted by 12 midnight EDT on 

March 20, 2007. 

ADDRESSES: Interested individuals and 

organizations should submit their 

responses to http://www.nigms.nih.gov/ 

About/StrategicPlan/Input.htm. 

SUPPLEMENTARY INFORMATION: 

Background 

The mission of the National Institute 

of General Medical Sciences (NIGMS) is 

to support basic research whose results 

lay the foundation for the diagnosis, 

treatment, and prevention of disease. 

NIGMS-funded researchers seek to 

answer important questions in fields 

such as cell biology, biophysics, 

genetics, developmental biology, 

pharmacology, physiology, 

biochemistry, chemistry, bioinformatics, 

and computational biology, and in 

selected cross-cutting clinical areas that 

affect multiple organ systems. NIGMS 

also provides leadership in promoting 

the diversity of the scientific workforce 

and in training the next generation of 

scientists to assure the vitality and 

continued productivity of basic 

research. 

NIGMS has embarked on a strategic 

planning process to identify Institute 

priorities to guide decision-making over 

the next five years. To assure the 

broadest possible input, NIGMS is 

inviting the scientists, scientific 

organizations, and other interested 

parties to respond electronically to a 

series of questions, listed below. 

• What factors should NIGMS 

consider in deciding how to set its 

priorities with respect to new and 

existing areas of support? 

• What factors should NIGMS 

consider in deciding how to set its 

priorities with respect to research 

training? 

• What new or emerging areas, 

approaches, or technologies in basic 

biomedical research should NIGMS 

pursue? 

• As part of its efforts to maintain a 

balanced research portfolio, how can 

NIGMS best encourage and support 

research that is highly innovative and/ 

or risky? 

• Are there areas of current NIGMS 

research activity that should receive less 

emphasis? 

• How can NIGMS enhance its 

communication with the scientific 

community and the public? 

• How can NIGMS more effectively 

promote and encourage greater diversity 

in the biomedical research workforce? 

You may also submit other comments 

relevant to NIGMS that are not 

specifically addressed in these 

questions. 

Responses will be limited to 

approximately 500 words per question. 

All information provided will be 

processed and analyzed with strict 

anonymity. 

Contact Person: Judith H. Greenberg, 

PhD., National Institute of General 

Medical Sciences, National Institutes of 


ycherry on PROD1PC64 with NOTICES